MarginsXMarginsX
Home › Markets › Health Care › INTS

Intensity Therapeutics Inc. (INTS)

INTS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.07
-0.32% on the day
Market cap
$10.1M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerINTS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2023
SEC CIK0001567264
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
11.2 months
$8.5M cash at September 30, 2026
Share count, 1 year
+37.4%
2025-11-05 to 2026-11-04 · +502.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result, the Company believes there is substantial doubt about its ability to continue as a going concern."
10-Q 2026-11-05
Cash and burn$8.5M cash; operating cash flow -$2.3M a quarter.Report 2026-09-30
Shares outstanding3,301,175 (2026-11-04); 60,064,965 a year earlier; 13,709,377 three years earlier. 1y figure adjusted for split (1-for-25 overall); 3y figure adjusted for split (1-for-25 overall).Cover page 2026-11-04
Reverse splits, 3 years1; latest 1-for-25 on 2026-02-19Source 2026-02-19
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-03-23
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2025-12-05
AuditorEisnerAmper LLP, New York, New York, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$3.5M-$2.5M$8.5MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$3.0M-$2.3M$9.5MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$2.4M-$1.8M$10.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$3.1M-$2.4M$11.9MNo debt tagsNeeds four quarters10-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$2.7M-$2.4M$7.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$2.5M-$2.5M$2.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$3.3M-$2.0M$929KNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$3.2M-$2.7M$2.6MNo debt tagsNeeds four quarters10-K 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-23
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 246 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.7%
1 month-13.2%
3 months-23.0%
Year to date-70.0%
1 year-74.2%
From 52-week high-79.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ALGSAligos Therapeutics Inc.$1.66-20.95%$10.4M
SCLXScilex Holding Company$1.25-12.59%$10.6M
TCRXTScan Therapeutics Inc.$0.1451-9.65%$9.2M
INABIN8bio Inc.$0.8160-0.49%$8.8M
BCDABioCardia Inc.$0.7901-4.92%$12.0M
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
PASGPassage Bio Inc.$4.13-2.82%$13.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier